90767-01-4

Basic information

• Product Name: 1-aMino-4-broMo-2-nitronaphthalene
• Synonyms: 1-aMino-4-broMo-2-nitronaphthalene;4-BroMo-2-nitronaphthalen-1-aMine
• CAS NO: 90767-01-4
• Molecular Formula: C₁₀H₇BrN₂O₂
• Molecular Weight: 267.07878
• EINECS: -0
• Mol File: 90767-01-4.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 1-aMino-4-broMo-2-nitronaphthalene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-aMino-4-broMo-2-nitronaphthalene(90767-01-4)
• EPA Substance Registry System: 1-aMino-4-broMo-2-nitronaphthalene(90767-01-4)

Safety Data

• Hazardous Substances Data: 90767-01-4(Hazardous Substances Data)

Usage

General Description

1-Amino-4-bromo-2-nitronaphthalene, also known as bromonitronaphthylamine, is a chemical compound with the molecular formula C10H7BrN2O2. It is a nitro-substituted naphthalene derivative that contains an amino group and a bromine atom. 1-aMino-4-broMo-2-nitronaphthalene is commonly used as a building block in the synthesis of various organic compounds and pharmaceutical products. It is also used as an intermediate in the production of dyes and pigments. 1-Amino-4-bromo-2-nitronaphthalene is a yellowish solid and is considered to be a potentially hazardous substance due to its reactivity and toxicity. It should be handled with care and stored and disposed of properly to prevent harm to human health and the environment.

Upstream product

• 7499-73-2 N-(4-bromo-2-nitronaphthalen-1-yl)acetamide 
• 64-17-5 ethanol 
• 7664-41-7 ammonia 

Downstream Products

• 7499-65-2 4-bromo-2-nitronaphthalene 
• 88-99-3 benzene-1,2-dicarboxylic acid 
• 5498-31-7 4-bromo-naphthalen-2-ol 
• 13243-65-7 2,3-Dibromo-1,4-naphthoquinone 
• 74924-94-0 4-bromonaphthalene-2-amine 
• 871901-53-0 N-(1-amino-4-bromo-[2]naphthyl)-benzenesulfonamide 
• 147397-60-2 3-methoxy-1-naphthoic acid 
• 147397-59-9 1-cyano-3-methoxynaphthalene 
• 1578179-15-3 2-(4-iodonaphthalen-2-ylamino)-5-nitrobenzoic acid 

Relevant articles and documents

KRAS G12D INHIBITORS

The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

Novel compound and organic light emitting device comprising the same

The present invention provides a novel compound and an organic light emitting device having same. The present invention also provides the organic light emitting device comprising: a first electrode; a second electrode facing the first electrode; and one or more organic substances provided between the first electrode and the second electrode.COPYRIGHT KIPO 2019

Monna, a potent and selective blocker for transmembrane protein with unknown function 16/anoctamin-1

Transmembrane protein with unknown function 16/anoctamin-1 (ANO1) is a protein widely expressed in mammalian tissues, and it has the properties of the classic calcium-activated chloride channel (CaCC). This protein has been implicated in numerous major physiological functions. However, the lack of effective and selective blockers has hindered a detailed study of the physiological functions of this channel. In this study, we have developed a potent and selective blocker for endogenous ANO1 in Xenopus laevis oocytes (xANO1) using a drug screening method we previously established (Oh et al., 2008). We have synthesized a number of anthranilic acid derivatives and have determined the correlation between biological activity and the nature and position of substituents in these derived compounds. A structure-activity relationship revealed novel chemical classes of xANO1 blockers. The derivatives contain a-NO2 group on position 5 of a naphthyl group-substituted anthranilic acid, and they fully blocked xANO1 chloride currents with an IC 5050 of 0.08 μM for xANO1. Selectivity tests revealed that other chloride channels such as bestrophin-1, chloride channel protein 2, and cystic fibrosis transmembrane conductance regulator were not appreciably blocked by 10～30 μM MONNA. The potent and selective blockers for ANO1 identified here should permit pharmacological dissection of ANO1/CaCC function and serve as potential candidates for drug therapy of related diseases such as hypertension, cystic fibrosis, bronchitis, asthma, and hyperalgesia.